Jiangsu Vcare's Next-Generation TRK Inhibitor VC004 Project Approved for Pivotal Phase II Clinical Trial
Published Time:
2023-11-01 17:18
Source:
Recently, the pivotal Phase II clinical study for Jiangsu Vcare Pharmaceutical Technology Co., Ltd.'s (Jiangsu Vcare) next-generation TRK inhibitor VC004 for treating NTRK fusion-positive solid tumors was approved by the NMPA. This clinical study will further evaluate the efficacy and safety of VC004 in patients with NTRK fusion mutations. Upon success, Jiangsu Vcare plans to submit an NDA in China.
VC004 is a next-generation TRK inhibitor independently developed by Jiangsu Vcare for the clinical treatment of solid tumors with NTRK fusion mutations. Phase I clinical data show an ORR of 80-90% in patients with NTRK fusion-positive solid tumors, with the longest DOR reaching 24 months. Efficacy data collection is ongoing. Preliminary efficacy was also observed in patients with brain metastases and those previously treated with TRK inhibitors, with over 60% of brain metastasis patients showing varying degrees of tumor shrinkage, including one case where the lesion nearly disappeared.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: "VC004 is a next-generation TRK inhibitor prioritized by our company. With its unique mechanism of action and the favorable safety profile and significant clinical efficacy demonstrated in early clinical studies, we believe it has the potential to be the leading drug among similar next-generation TRK inhibitors. The approval for this pivotal Phase II clinical trial signifies full recognition and positive affirmation of VC004's pre-clinical and clinical development progress. We will accelerate its subsequent clinical development process, expediting the exploration of its safety and efficacy in patients with NTRK fusion-positive solid tumors, striving to bring this resistance-overcoming TRK targeted therapy to cancer patients as soon as possible."
About VC004
VC004 is a Class I targeted agent independently developed by Jiangsu Vcare. As a next-generation TRK inhibitor, it is expected to provide a treatment option for patients with NTRK fusion mutations, addressing the unmet clinical need for anti-resistance therapy globally. As a next-generation therapeutic, VC004 demonstrates excellent clinical efficacy and safety. Currently, no next-generation resistance-overcoming inhibitor drugs are marketed globally. VC004 has the potential to become a leading next-generation TRK inhibitor worldwide.
About NTRK Fusion-Positive Solid Tumors
NTRK gene fusions have been identified as oncogenic drivers in both adult and pediatric patients with a wide range of solid tumors. The NTRK genes (NTRK1, NTRK2, and NTRK3) encode the TRKA, TRKB, and TRKC receptors of the TRK family. These fusions act as drivers in multiple cancers and are found across numerous solid tumor types. Currently, NTRK fusion inhibitors show remarkable efficacy in the clinical practice, holding immense potential in the field of oncology. In China, NTRK gene fusion mutations are found in prevalent cancer types such as lung cancer, colorectal cancer, breast cancer, and thyroid cancer, especially high prevalence in certain rare cancers, including secretory breast carcinoma and salivary gland secretory carcinoma.
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn